Floatz logo

Tofacitinib

Psoriasis Vulgaris

PfizerSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Psoriasis Vulgaris cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Amgen
Phase 4BBB
Calcipotriene
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Semaglutide
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Tirzepatide
Eli Lilly and Company
Phase 4BBB
cp-690,550
Pfizer
Phase 3BBB

View all 28 →

Same molecule, other indications

Tofacitinib is also rated in:

psoriasisDormant
B
Indicative ·
57 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
rheumatoid arthritisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →